COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
NanoViricides, Inc. comments on the potential of ultra-broad-spectrum antiviral NV-387 against bird flu H5N1 viruses. The company's drug candidate shows promising results in lethal animal model studies -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Covestro AG: Covestro AG enters into concrete negotiations with Adnoc regarding a potential transaction
Covestro AG enters concrete negotiations with Adnoc for a potential transaction, with a possible offer price of €62 per share. Discussions aim to reach mutual agreement on core aspects -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on APONTIS PHARMA AG with a Buy rating and EUR 17.00 price target. Apontis focuses on cardiovascular and respiratory drugs in Germany, led by CEO Wohlschlegel to drive efficiency and growth
